(Total Views: 398)
Posted On: 06/13/2023 10:25:20 PM
Post# of 148892
October 10th 2019, Health Organization NSF International is buying the majority stake of CRO Amarex Clinical Research...An NSF international company.
NSF International President and CEO Kevan Lawlor said in a news release__
"Amarex brings clinical trial expertise (slight exaggeration) to NSF International's large base of training, quality and consulting clients and Amarex's CRO clients may now benefit (slight exaggeration) from NSF International"s global reach and expertise to save time and reduce unnecessary costs (slight exaggeration).
October 7th 2021 Cytodyn announces legal actions against it's CRO.
Kevan Lawlor is the executive...Drano is referencing.
NSF International President and CEO Kevan Lawlor said in a news release__
"Amarex brings clinical trial expertise (slight exaggeration) to NSF International's large base of training, quality and consulting clients and Amarex's CRO clients may now benefit (slight exaggeration) from NSF International"s global reach and expertise to save time and reduce unnecessary costs (slight exaggeration).
October 7th 2021 Cytodyn announces legal actions against it's CRO.
Kevan Lawlor is the executive...Drano is referencing.
(1)
(0)Scroll down for more posts ▼
